Breast Cancer | Specialty

"Angelina Jolie Effect" Sparks More BRCA Testing at Cancer Center

September 2nd 2014

The actress Angelina Jolie's decision to undergo a preventive double mastectomy after learning she carried the BRCA1 gene mutation-associated with an increased risk of breast and/or ovarian cancer-apparently sparked an "Angelina effect" on public health.

Subtype, pCR Predict Locoregional Recurrence Following Neoadjuvant Therapy

September 2nd 2014

The combination of multiple independent factors minimized the impact of baseline stage for predicting locoregional recurrence (LRR) following neoadjuvant chemotherapy in patients with breast cancer, according to a large retrospective analysis presented in advance of the 2014 Breast Cancer Symposium.

Patient Decisions About Bilateral Mastectomy Influenced by Anxiety, Worry About Recurrence

September 2nd 2014

One of the first studies to prospectively examine women's breast surgery preferences has revealed that newly diagnosed women with breast cancer who decide to undergo contralateral prophylactic mastectomy (CPM), may be making this decision as result of high anxiety and fear of recurrence, rather than relying on evidence-based information.

Some Surgical Complications Greater With Bilateral Versus Unilateral Mastectomy

September 2nd 2014

Postsurgery complications are infrequent among breast cancer patients undergoing surgery with reconstruction; however, according to a large database study, the rates of certain complications, including reoperation, blood transfusion, and implant loss, are higher with bilateral mastectomy versus unilateral mastectomy.

Signed Letters From Family Physicians May Increase Mammography Screening Rates

September 2nd 2014

Women who received signed letters from their family physician along with scheduled postcard reminders are more likely to return for mammography screening than women who only received a postcard

Dr. Isaacs on the Importance of Genetic Counseling

September 2nd 2014

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses the importance of genetic counseling and the role of the genetic counselor

Dr. Arkenau Discusses AZD4547 and FGFR Amplification in Advanced Solid Tumors

August 28th 2014

Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Canon Research Institute, discusses an exploratory analysis of AZD4547 in patients with advanced tumors.

Novel Breast Cancer Agents Aimed at Overcoming Endocrine Therapy Resistance

August 28th 2014

Although advances in endocrine therapy for women with estrogen receptor (ER)-positive breast cancer have been made in recent years, de novo and acquired resistance to treatments remain important clinical problems, and efforts to identify effective modalities to overcome this challenge continue.

O'Shaughnessy Provides Fresh Insights Into Specificity in TNBC Therapy

August 25th 2014

Although no cytotoxic agents are currently correlated with specific subtypes of triple negative breast cancer (TNBC), recent findings indicate that targeting genomic stability, antimetastatic mechanisms, and protein expression characteristics are promising approaches for future TNBC treatments.

Dr. Pagani Discusses Aromatase Inhibitors for Premenopausal Women with Breast Cancer

August 22nd 2014

Olivia Pagani, MD, Institute of Oncology, Southern Switzerland, discusses the result of a joint analysis of two phase III trials involving a total of 4690 premenopausal women with hormone-receptor–positive (HR+) breast cancer who were treated with the aromatase inhibitor exemestane.

Dr. Brufsky on Adjuvant Bisphosphonates for Patients with Breast Cancer

August 21st 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses whether or not adjuvant bisphosphonates are ready to be a new standard of care in breast cancer.

DHEA Therapy Offers Relief From Vaginal Symptoms in Cancer Survivors

August 21st 2014

A randomized multicenter trial examining the efficacy of adding dehydroepiandosterone (DHEA) to a vaginal bioadhesive moisturizer in postmenopausal survivors of breast or gynecologic cancer has found that daily rather than as-needed use of such a moisturizer significantly relieves symptoms of vaginal atrophy in these women.

Suzanne Fuqua Discusses the Y537 Hotspot in Breast Cancer

August 18th 2014

Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses the Y537 hotspot in breast cancer.

Pfizer Seeks FDA Approval for Palbociclib

August 18th 2014

Pfizer has submitted a New Drug Application for palbociclib plus letrozole as a frontline treatment for postmenopausal women with ER-positive, HER2-negative advanced breast cancer, based on findings from the phase II PALOMA-1 trial.

Dr. O'Regan Discusses Updates in HER2-Positive Breast Cancer

August 14th 2014

Ruth M. O'Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses updates in the field of adjuvant therapy for HER2-positive breast cancer.

Favorable Safety Profile of T-DM1 Confirmed in Large Study

August 13th 2014

The favorable safety profile of T-DM1 makes it apt to be looked at in other settings of breast cancer.

Tripathy Offers Perspective on HER2-Positive Breast Cancer

August 13th 2014

The ever-evolving treatment landscape for patients with HER2-positive breast cancer leaves several questions unanswered regarding therapeutic sequences and whether an optimal standard of care exists.

Dr. Brufsky Discusses Future Research into Bisphosphonates

August 11th 2014

Adam M. Brufsky, MD, PhD, professor of medicine, associate chief, Division of Hematology/Oncology, University of Pittsburgh, discusses future research into bisphosphonates.

Utilizing Bisphosphonates in Breast Cancer

August 7th 2014

TEXT/SOFT Findings in HR-Positive Breast Cancer

August 7th 2014